1. Home
  2. QURE
  3. QURE News

Latest uniQure N.V. (QURE) News on July 16, 2025

Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
QURE

Insider Monkey

23 days ago

Lake Street: AMT-130 Could Be Game-Changer For ClearPoint

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
QURE

GlobeNewswire

a month ago

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint
QURE

TipRanks

a month ago

Lake Street says AMT-130 could be ‘significantly impactful’ for ClearPoint

QURE

MT Newswires

a month ago

UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
QURE

GlobeNewswire

a month ago

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
QURE

GlobeNewswire

2 months ago

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
QURE

GlobeNewswire

2 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE

Zacks

2 months ago

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...
QURE

GuruFocus.com

2 months ago

uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ...

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates
QURE

Zacks

2 months ago

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

QURE

Associated Press Finance

2 months ago

UniQure: Q1 Earnings Snapshot

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress
QURE

GlobeNewswire

2 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

uniQure to Announce First Quarter 2025 Financial Results
QURE

GlobeNewswire

2 months ago

uniQure to Announce First Quarter 2025 Financial Results

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
QURE

Zacks

3 months ago

CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
QURE

Zacks

3 months ago

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
QURE

Pharmaceutical Technology

3 months ago

FDA grants breakthrough status to uniQure’s Huntington’s disease therapy

QURE

MT Newswires

3 months ago

Top Midday Gainers

QURE

MT Newswires

3 months ago

Update: UniQure Shares Rise After Gene Therapy for Huntington's Gets FDA Breakthrough Designation

QURE

MT Newswires

3 months ago

UniQure's Huntington's Drug Gets FDA Breakthrough Therapy Designation

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
QURE

GlobeNewswire

3 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

QURE

MT Newswires

4 months ago

Uniqure Insider Sold Shares Worth $291,629, According to a Recent SEC Filing

uniQure Full Year 2024 Earnings: Misses Expectations
QURE

Simply Wall St.

5 months ago

uniQure Full Year 2024 Earnings: Misses Expectations

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
QURE

Zacks

5 months ago

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

5 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
QURE

Simply Wall St.

5 months ago

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
QURE

Benzinga

5 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
QURE

PR Newswire

5 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

QURE

MT Newswires

5 months ago

UniQure Advances AMT-191 Trial in Fabry Disease

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

5 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

QURE

MT Newswires

6 months ago

UniQure Gets Favorable Recommendation From Data Monitoring Committee AMT-162 Trial to Treat Amyotrophic Lateral Sclerosis

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
QURE

GlobeNewswire

6 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?
QURE

Insider Monkey

6 months ago

Is uniQure N.V. (QURE) the Most Promising Growth Stock According to Wall Street Analysts?

Here’s Why uniQure N.V. (QURE) Is Skyrocketing
QURE

Insider Monkey

6 months ago

Here’s Why uniQure N.V. (QURE) Is Skyrocketing

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?
QURE

Insider Monkey

6 months ago

Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?

QURE

MT Newswires

6 months ago

uniQure Prices $75 Million Public Offering; Shares Fall

uniQure Announces Pricing of its Public Offering
QURE

GlobeNewswire

6 months ago

uniQure Announces Pricing of its Public Offering

QURE

MT Newswires

6 months ago

uniQure Launches Public Offering of Shares, Pre-Funded Warrants

QURE

MT Newswires

6 months ago

UniQure Files Mixed Shelf; Shares Fall After Hours

uniQure Announces Proposed Public Offering
QURE

GlobeNewswire

6 months ago

uniQure Announces Proposed Public Offering

QURE

MT Newswires

6 months ago

RBC Raises Price Target on uniQure to $24 From $20, Keeps Outperform, Speculative Risk

uniQure price target raised to $32 from $12 at Stifel
QURE

TipRanks

7 months ago

uniQure price target raised to $32 from $12 at Stifel

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
QURE

Motley Fool

7 months ago

Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?

QURE

MT Newswires

7 months ago

Uniqure Insider Sold Shares Worth $1,503,000, According to a Recent SEC Filing

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
QURE

Zacks

7 months ago

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
QURE

Zacks

7 months ago

Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More

QURE

MT Newswires

7 months ago

RBC Raises Price Target on uniQure to $20 From $14, Keeps Outperform, Speculative Risk

QURE

MT Newswires

7 months ago

UniQure Gets Rating Upgrade From Wells Fargo After Agreement With FDA -- Shares Continue Rally

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
QURE

Investor's Business Daily

7 months ago

UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
QURE

Investor's Business Daily

7 months ago

UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug

QURE

MT Newswires

7 months ago

UniQure Says Aligned With FDA on Approval Pathway for Huntington's Disease Drug; Shares Jump

UniQure shares soar on chance of speedy approval for Huntington’s therapy
QURE

BioPharma Dive

7 months ago

UniQure shares soar on chance of speedy approval for Huntington’s therapy

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease
QURE

GlobeNewswire

7 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease

Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?
QURE

Simply Wall St.

7 months ago

Is uniQure N.V. (NASDAQ:QURE) Trading At A 39% Discount?

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
QURE

Zacks

8 months ago

Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet

What Makes uniQure (QURE) a New Buy Stock
QURE

Zacks

8 months ago

What Makes uniQure (QURE) a New Buy Stock

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
QURE

GlobeNewswire

8 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade
QURE

Zacks

8 months ago

Wall Street Analysts Believe uniQure (QURE) Could Rally 169.18%: Here's is How to Trade

What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates
QURE

Simply Wall St.

8 months ago

What Does The Future Hold For uniQure N.V. (NASDAQ:QURE)? These Analysts Have Been Cutting Their Estimates

uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
QURE

Simply Wall St.

8 months ago

uniQure Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates
QURE

Zacks

8 months ago

UniQure (QURE) Reports Q3 Loss, Lags Revenue Estimates

QURE

Associated Press Finance

8 months ago

UniQure: Q3 Earnings Snapshot

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

8 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth
QURE

Zacks

9 months ago

Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
QURE

Zacks

9 months ago

UniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

State Street Corp's Strategic Reduction in uniQure NV Holdings
QURE

GuruFocus.com

9 months ago

State Street Corp's Strategic Reduction in uniQure NV Holdings

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS
QURE

GlobeNewswire

9 months ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS
QURE

GlobeNewswire

9 months ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
QURE

Zacks

9 months ago

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?

QURE

MT Newswires

10 months ago

UniQure's Gets Orphan Drug Designation From FDA for Fabry Disease Treatment

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

10 months ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago
QURE

Simply Wall St.

10 months ago

uniQure (NASDAQ:QURE) investors are sitting on a loss of 88% if they invested five years ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease
QURE

GlobeNewswire

a year ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
QURE

Simply Wall St.

a year ago

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know

UniQure restructuring to claim 300 jobs
QURE

BioPharma Dive

a year ago

UniQure restructuring to claim 300 jobs

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
QURE

Zacks

a year ago

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates

QURE

Associated Press Finance

a year ago

UniQure: Q2 Earnings Snapshot

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
QURE

GlobeNewswire

a year ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
QURE

Zacks

a year ago

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?

QURE

MT Newswires

a year ago

UniQure Completes Sale of Facility to Genezen

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen
QURE

GlobeNewswire

a year ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure’s shares soar on positive data for Huntington’s gene therapy
QURE

Clinical Trials Arena

a year ago

uniQure’s shares soar on positive data for Huntington’s gene therapy

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
QURE

Zacks

a year ago

Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet
QURE

Zacks

a year ago

Wall Street Analysts Think uniQure (QURE) Could Surge 195.8%: Read This Before Placing a Bet

uniQure (QURE) Soars on New Huntington's Disease Study Data
QURE

Zacks

a year ago

uniQure (QURE) Soars on New Huntington's Disease Study Data

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?
QURE

Zacks

a year ago

uniQure (QURE) Surges 76.5%: Is This an Indication of Further Gains?

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)
QURE

Zacks

a year ago

Down -29.74% in 4 Weeks, Here's Why You Should You Buy the Dip in uniQure (QURE)

UniQure stock surges on data for Huntington’s gene therapy
QURE

BioPharma Dive

a year ago

UniQure stock surges on data for Huntington’s gene therapy

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
QURE

GlobeNewswire

a year ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%
QURE

Simply Wall St.

a year ago

uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 52%

QURE

MT Newswires

a year ago

uniQure's Commercial Gene Therapy Operations to be Acquired by Genezen

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen
QURE

GlobeNewswire

a year ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA
QURE

PR Newswire

a year ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

UniQure, with sale of plant, outsources Hemgenix manufacturing
QURE

BioPharma Dive

a year ago

UniQure, with sale of plant, outsources Hemgenix manufacturing

QURE

MT Newswires

a year ago

UniQure Shares Rise After US FDA Grants Regenerative Medicine Advanced Designation for Huntington's Treatment

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
QURE

GlobeNewswire

a year ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease

uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
QURE

Simply Wall St.

a year ago

uniQure First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

QURE

Associated Press Finance

a year ago

UniQure: Q1 Earnings Snapshot

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
QURE

GlobeNewswire

a year ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

13 Best Biotech Stocks To Buy Under $20
QURE

Insider Monkey

a year ago

13 Best Biotech Stocks To Buy Under $20

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates
QURE

Simply Wall St.

a year ago

uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates

Share on Social Networks: